These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

248 related articles for article (PubMed ID: 38889284)

  • 1. Immune checkpoint inhibitor use in head and neck squamous cell carcinoma: the current landscape and future perspectives.
    Gatfield ER; Tadross J; Ince W
    Future Oncol; 2024; 20(23):1695-1711. PubMed ID: 38889284
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Enhancing programmed cell death protein 1 axis inhibition in head and neck squamous cell carcinoma: Combination immunotherapy.
    Vathiotis IA; Johnson JM; Argiris A
    Cancer Treat Rev; 2021 Jun; 97():102192. PubMed ID: 33819755
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Current landscape of immunotherapy trials in locally advanced and high-risk head and neck cancer.
    Park R; Park JC
    Immunotherapy; 2021 Aug; 13(11):931-940. PubMed ID: 34100301
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Advancements in neoadjuvant immune checkpoint inhibitor therapy for locally advanced head and neck squamous Carcinoma: A narrative review.
    Li J; Luo Z; Jiang S; Li J
    Int Immunopharmacol; 2024 Jun; 134():112200. PubMed ID: 38744175
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of squamous cell carcinoma of the head and neck (HNSCC).
    Cohen EEW; Bell RB; Bifulco CB; Burtness B; Gillison ML; Harrington KJ; Le QT; Lee NY; Leidner R; Lewis RL; Licitra L; Mehanna H; Mell LK; Raben A; Sikora AG; Uppaluri R; Whitworth F; Zandberg DP; Ferris RL
    J Immunother Cancer; 2019 Jul; 7(1):184. PubMed ID: 31307547
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Less is more: Exploring neoadjuvant immunotherapy as a de-escalation strategy in head and neck squamous cell carcinoma treatment.
    Cao LM; Zhong NN; Chen Y; Li ZZ; Wang GR; Xiao Y; Liu XH; Jia J; Liu B; Bu LL
    Cancer Lett; 2024 Aug; 598():217095. PubMed ID: 38964728
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Introducing Checkpoint Inhibitors Into the Curative Setting of Head and Neck Cancers: Lessons Learned, Future Considerations.
    Nenclares P; Rullan A; Tam K; Dunn LA; St John M; Harrington KJ
    Am Soc Clin Oncol Educ Book; 2022 Apr; 42():1-16. PubMed ID: 35522916
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Therapeutic Approaches With Immune Checkpoint Inhibitors in Head and Neck Cancers and the Role of PD-L1 as a Biomarker.
    Oualla K; Castelo Branco L; Nouiyakh L; Amaadour L; Benbrahim Z; Arifi S; Mellas N
    Cancer Control; 2021; 28():10732748211004878. PubMed ID: 33827280
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immunotherapy Advances in Locally Advanced and Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma and Its Relationship With Human Papillomavirus.
    Wang H; Zhao Q; Zhang Y; Zhang Q; Zheng Z; Liu S; Liu Z; Meng L; Xin Y; Jiang X
    Front Immunol; 2021; 12():652054. PubMed ID: 34305889
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The Evolving Landscape of PD-1/PD-L1 Pathway in Head and Neck Cancer.
    Qiao XW; Jiang J; Pang X; Huang MC; Tang YJ; Liang XH; Tang YL
    Front Immunol; 2020; 11():1721. PubMed ID: 33072064
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immunomethylomic profiles of long-term head and neck squamous cell carcinoma survivors on immune checkpoint inhibitors.
    Lee MK; Zhang Z; Sehgal K; Butler R; Stolrow H; Ramush G; Shirai K; Koestler DC; Salas LA; Wiencke JK; Haddad R; Kelsey KT; Christensen BC
    Epigenomics; 2024; 16(11-12):799-807. PubMed ID: 38869472
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Identification of factors related to immunotherapy efficacy and prognosis in patients with advanced head and neck squamous cell carcinoma.
    Xu X; Li R; Zhang L; Zhu G; Ren D; Wu L; Gong X
    Diagn Pathol; 2021 Nov; 16(1):110. PubMed ID: 34823553
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immunotherapies and Future Combination Strategies for Head and Neck Squamous Cell Carcinoma.
    Cristina V; Herrera-Gómez RG; Szturz P; Espeli V; Siano M
    Int J Mol Sci; 2019 Oct; 20(21):. PubMed ID: 31671550
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Feasibility of Near-infrared Photoimmunotherapy Combined With Immune Checkpoint Inhibitor Therapy in Unresectable Head and Neck Cancer.
    Hirakawa H; Ikegami T; Kinjyo H; Hayashi Y; Agena S; Higa T; Kondo S; Toyama M; Maeda H; Suzuki M
    Anticancer Res; 2024 Sep; 44(9):3907-3912. PubMed ID: 39197908
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The immune checkpoint inhibitors treatment of head and neck squamous cell carcinoma: an expert consensus.
    Liu L; Xiang Z; Li Y; Guo W; Yang K; Wang J; Sun Z; Ren G; Zhang J; Sun M; Ran W; Huang G; Tang Z; Li L
    Hua Xi Kou Qiang Yi Xue Za Zhi; 2022 Dec; 40(6):619-628. PubMed ID: 36416313
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Predictive capacity of immune-related adverse events and cytokine profiling in neoadjuvant immune checkpoint inhibitor trials for head and neck squamous cell carcinoma.
    Alnemri AE; Tekumalla S; Moroco AE; Vathiotis I; Tuluc M; Gargano S; Zhan T; Cognetti DM; Curry JM; Argiris A; Linnenbach A; South AP; Harshyne LA; Johnson JM; Luginbuhl AJ
    Cancer Med; 2024 Jun; 13(11):e7370. PubMed ID: 38847087
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Breaking Ground in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: Novel Therapies Beyond PD-L1 Immunotherapy.
    Rosenberg AJ; Perez CA; Guo W; de Oliveira Novaes JM; da Silva Reis KFO; McGarrah PW; Price KAR
    Am Soc Clin Oncol Educ Book; 2024 Jun; 44(3):e433330. PubMed ID: 38718318
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hypoalbuminemia and hypercalcemia are independently associated with poor treatment outcomes of anti-PD-1 immune checkpoint inhibitors in patients with recurrent or metastatic head and neck squamous cell carcinoma.
    Chiu TJ; Huang TL; Chien CY; Huang WT; Li SH
    World J Surg Oncol; 2024 Sep; 22(1):242. PubMed ID: 39256833
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Safety and efficacy of cetuximab-containing chemotherapy after immune checkpoint inhibitors for patients with squamous cell carcinoma of the head and neck: a single-center retrospective study.
    Kurosaki T; Mitani S; Tanaka K; Suzuki S; Kanemura H; Haratani K; Fumita S; Iwasa T; Hayashi H; Yoshida T; Ishikawa K; Kitano M; Otsuki N; Nishimura Y; Doi K; Nakagawa K
    Anticancer Drugs; 2021 Jan; 32(1):95-101. PubMed ID: 32976215
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Neoadjuvant immunoradiotherapy results in high rate of complete pathological response and clinical to pathological downstaging in locally advanced head and neck squamous cell carcinoma.
    Leidner R; Crittenden M; Young K; Xiao H; Wu Y; Couey MA; Patel AA; Cheng AC; Watters AL; Bifulco C; Morris G; Rushforth L; Nemeth S; Urba WJ; Gough M; Bell RB
    J Immunother Cancer; 2021 May; 9(5):. PubMed ID: 33963014
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.